Asthma Disease

Global Asthma Disease Market to Reach US$39.2 Billion by 2030

The global market for Asthma Disease estimated at US$26.2 Billion in the year 2024, is expected to reach US$39.2 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Pediatrics, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$25.9 Billion by the end of the analysis period. Growth in the Adults segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.1 Billion While China is Forecast to Grow at 11.2% CAGR

The Asthma Disease market in the U.S. is estimated at US$7.1 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$8.3 Billion by the year 2030 trailing a CAGR of 11.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Asthma Disease Market – Key Trends & Drivers Summarized

How Is the Global Understanding of Asthma Evolving with Scientific Advances and Epidemiological Trends?

Asthma, a chronic inflammatory disease of the airways, continues to be one of the most prevalent and complex respiratory disorders globally, affecting people of all ages, geographies, and socioeconomic backgrounds. With over 300 million individuals estimated to be living with asthma worldwide, the condition represents a major public health concern. Recent advances in epidemiology and immunology have deepened the understanding of asthma as a heterogeneous disease with multiple phenotypes and endotypes, rather than a one-size-fits-all condition. This new understanding has reshaped the way asthma is diagnosed and managed, highlighting the need for personalized treatment strategies. While genetic predisposition remains a major risk factor, environmental influences such as pollution, allergens, occupational irritants, and urbanization are increasingly implicated in disease onset and exacerbation. The rise in asthma prevalence, particularly in low- and middle-income countries, reflects changing lifestyles, increased industrialization, and underdiagnosis. Asthma’s burden is not limited to physical symptoms such as wheezing, breathlessness, and coughing, but also includes psychological distress, reduced quality of life, and significant economic costs. Seasonal variations, respiratory infections, and comorbidities such as obesity and allergic rhinitis further complicate disease management. The growing body of research on asthma triggers, immune pathways, and the microbiome is paving the way for innovative diagnostic tools and targeted therapies. Despite being a manageable disease, asthma still leads to preventable hospitalizations and deaths due to disparities in access to care, inconsistent adherence to treatment, and lack of awareness. As scientific insight into the disease deepens, it is becoming increasingly clear that asthma requires a multifactorial, evidence-based, and individualized approach to effectively reduce its global impact.

What Medical and Technological Innovations Are Transforming Asthma Diagnosis and Treatment?

The management of asthma has evolved significantly with the integration of medical innovation and digital technologies that enhance early diagnosis, continuous monitoring, and targeted treatment. Traditional approaches that rely solely on inhaled corticosteroids and bronchodilators are giving way to more sophisticated treatment paradigms driven by advances in biologics, precision medicine, and digital health. Biologic therapies such as monoclonal antibodies targeting specific inflammatory pathways like IL-5, IL-4, and IgE are revolutionizing treatment for patients with severe, eosinophilic, or allergic asthma who do not respond well to conventional medications. These targeted therapies are improving outcomes by reducing exacerbation rates, improving lung function, and minimizing dependence on oral corticosteroids. On the diagnostic front, tools like fractional exhaled nitric oxide (FeNO) testing and blood eosinophil counts are helping physicians more accurately classify asthma phenotypes and adjust therapies accordingly. Portable spirometry devices and digital peak flow meters allow patients to monitor lung function at home, providing valuable real-time data that supports self-management and early intervention. The rise of mobile apps and connected inhalers with embedded sensors enables tracking of medication adherence, symptom patterns, and environmental triggers, empowering patients while providing clinicians with actionable insights. Artificial intelligence is being explored to predict exacerbations and personalize treatment plans based on historical data and real-world evidence. Smart inhalers that sync with mobile devices can alert users to missed doses or incorrect inhaler techniques, addressing two of the most common challenges in asthma care. These innovations are creating a more responsive and patient-centered care model, helping to bridge the gap between routine treatment and precision-based asthma management.

How Do Socioeconomic Factors, Lifestyle Changes, and Environmental Pressures Impact Asthma Outcomes?

Asthma outcomes are profoundly influenced by a complex interplay of socioeconomic determinants, environmental exposures, and evolving lifestyle habits that vary widely across populations and regions. In urban areas, exposure to air pollution from traffic emissions, industrial waste, and construction dust significantly increases the risk of asthma onset and exacerbation, particularly in children and the elderly. Indoor air quality, influenced by factors such as secondhand smoke, mold, and household allergens, also plays a critical role, especially in low-income settings where housing conditions may be poor. The increasing adoption of sedentary lifestyles and rising rates of obesity are emerging as contributors to poor asthma control, with research indicating a link between metabolic disorders and heightened airway inflammation. In addition, disparities in healthcare access, insurance coverage, and health literacy contribute to inconsistent diagnosis, delayed treatment initiation, and suboptimal disease control. In many developing countries, the absence of specialized respiratory care, lack of affordable medications, and limited availability of diagnostic tools hinder effective management, leading to higher rates of emergency visits and hospitalizations. Cultural beliefs and stigma surrounding chronic illnesses may also affect treatment adherence and care-seeking behavior. Climate change is adding another layer of complexity by altering pollen seasons, increasing the frequency of wildfires, and intensifying heat waves, all of which can worsen respiratory symptoms. Moreover, stress, mental health issues, and comorbid conditions such as depression and anxiety are increasingly recognized as factors that exacerbate asthma symptoms and negatively impact patient outcomes. Addressing these broader determinants of health through public policy, education, and community-based interventions is essential to reducing disparities and improving asthma care globally.

What Is Driving the Continued Global Growth of the Asthma Disease Management Market?

The growth in the asthma disease management market is driven by several converging factors, including rising disease prevalence, increasing awareness, advances in therapeutic options, and expanding use of digital health solutions. A growing global population, coupled with increased urbanization and pollution, has led to higher incidence and diagnosis rates of asthma across all age groups. Heightened public and clinical awareness has resulted in more proactive screening, especially in pediatric populations where early intervention can alter disease progression. Pharmaceutical innovations, particularly in the area of biologics and combination inhalers, are expanding the treatment arsenal, allowing for more tailored and effective interventions. The shift toward value-based healthcare is encouraging the adoption of comprehensive asthma management programs that focus on prevention, education, and adherence. Governments and health organizations are investing in public health campaigns, school-based awareness programs, and guidelines that emphasize asthma control and self-management. Insurance coverage for advanced therapies and digital tools is also becoming more widespread, making them accessible to a broader patient population. Technological advancements are enabling the development of integrated care platforms that bring together patients, providers, and payers in a coordinated ecosystem. The increasing popularity of remote care, especially post-pandemic, has accelerated the adoption of telemedicine and home-monitoring solutions for asthma. In parallel, research into the genetic and environmental underpinnings of asthma continues to yield insights that could pave the way for even more precise and preventive strategies. These diverse drivers are collectively contributing to sustained growth in the global asthma market, highlighting the need for ongoing innovation and collaboration to improve outcomes and quality of life for individuals living with this chronic respiratory condition.

SCOPE OF STUDY:

The report analyzes the Asthma Disease market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Age Group (Pediatrics, Adults)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

• AbbVie
• AstraZeneca
• Bayer
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Circassia Pharmaceuticals
• Cipla
• GSK (GlaxoSmithKline)
• Hikma Pharmaceuticals
• Hyphens Pharma
• Janssen Pharmaceuticals (J&J)
• Mylan (now part of Viatris)
• Novartis
• Omega Pharma
• Sanofi
• Sandoz (Novartis)
• Teva Pharmaceuticals
• UCB
• Vectura Group
• Veracyte

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more